The Short Version
The evidence supports a higher overall safety risk for compounded or unapproved peptide injections than for approved prescription peptide medicines. These products may lack FDA premarket review, standardized manufacturing controls, and verified purity or potency, increasing risks such as contamination and immune reactions. Proper pharmacy compounding is generally safer than gray-market use, but it still does not provide the same assurances as an approved product.